Abstract:Objective: To evaluate differences of EML4-ALK positive rates in tissues samples between immunohistochemistry, reverse transcriptase polymerase chain reaction and the next-generation sequencing method. Besides, to compare the differences of EML4-ALK positive rates in blood samples and tissue samples by next-generation sequencing. The results provide a basis for the selection of a suitable EML4-ALK fusion gene detection method. Methods: Immunohistochemistry analysis of EML4-ALK in tumors was performed on samples from 2631 patients with non-small cell lung cancer. The mutation of EML4-ALK in the tissue samples of 399 patients with non-small cell lung cancer was detected by reverse transcription polymerase chain reaction. Next-generation sequencing was used to detect the mutation of EML4-ALK in 1505 non-small cell lung cancer patients, including 1208 tissue samples and 297 blood samples. Results: The positive incidence of EML4-ALK by immunohistochemistry was 7.11% (187/2631). Histologically, 9.51% (170/1787) of the samples were lung adenocarcinomas, and 2.01% (17/844) were squamous cell carcinomas. The positive rate of EML4-ALK was 8.52% (34/399) in 399 patients with non-small cell lung cancer, as detected by reverse transcription polymerase chain reaction; the mutation rate of adenocarcinoma was 11.62% (33/284), and the mutation rate of squamous cell carcinoma was 0.86% (1/115). In 1208 patients with non-small cell lung cancer with tissue samples, the positive rate of EML4-ALK was 4.88% (59/1208), as determined by next-generation sequencing, the mutation rate of adenocarcinoma was 5.84% (58/994), and the mutation rate of squamous cell carcinoma was 0.47% (1/214). The positive rate of EML4-ALK detected by reverse transcription polymerase chain reaction was higher than that detected by immunohistochemistry. Compared with the next-generation sequencing results, the positive rates of EML4-ALK detected by immunohistochemistry and reverse transcription polymerase chain reaction were higher, and the differences were significant (p<0.05). In blood samples from 297 patients with non-small cell lung cancer, the positive rate of EML4-ALK detected by next-generation sequencing was 3.70% (11/297), the mutation rate of adenocarcinoma was 3.82% (10/262), and the mutation rate of squamous cell carcinoma was 2.86% (1/35). The EML4-ALK positive rate of the tissue samples was thus higher than that of the blood biopsy samples. Conclusion: Among the three methods for detecting EML4-ALK, reverse transcription polymerase chain reaction has the highest positive rate, followed by immunohistochemistry, and next-generation sequencing has the lowest positive rate. The positive detection rate of EML4-ALK in tissue samples by next-generation sequencing was higher than that in blood samples.

Comparison of Small Biopsy Specimens and Surgical Specimens for the Detection of Egfr Mutations and Eml4-Alk in Non-Small-Cell Lung Cancer

Detection of Epidermal Growth Factor Receptor Mutations in Small Specimens of Non-Small Cell Lung Cancer by Amplification Refractory Mutation System

Peripheral Blood for Epidermal Growth Factor Receptor Mutation Detection in Non-Small Cell Lung Cancer Patients

Feasibility of Cytological Specimens for ALK Fusion Detection in Patients with Advanced NSCLC Using the Method of RT-PCR.

Association of EGFR Mutation or ALK Rearrangement with Expression of DNA Repair and Synthesis Genes in Never‐smoker Women with Pulmonary Adenocarcinoma

Comparative analysis of clinicoradiologic characteristics of lung adenocarcinomas with ALK rearrangements or EGFR mutations

Comparison Between ADx-ARMS and PCR-Sanger Sequencing for EGFR Mutation Detection in Small Biopsy Samples of Non Small Cell Lung Cancer

Screening of Nsclc Samples from Chinese Lung Cancer Patients for Activating Rearrangements of the Alk, Ret, and Ros1 Genes.

CT-guided aspiration lung biopsy for EGFR and ALK gene mutation analysis of lung cancer

Accurate and Economical Detection of ALK Positive Lung Adenocarcinoma with Semiquantitative Immunohistochemical Screening

Suitability of Surgical Tumor Tissues, Biopsy, or Cytology Samples for Epidermal Growth Factor Receptor Mutation Testing in Non–Small Cell Lung Carcinoma Based on Chinese Population

Comparison of clinical and radiological characteristics between anaplastic lymphoma kinase rearrangement and epidermal growth factor receptor mutation in treatment naïve advanced lung adenocarcinoma.

Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer

Comparing Genomic Profiles of ALK Fusion-Positive and ALK Fusion-Negative Nonsmall Cell Lung Cancer Patients

Detection of EML4-ALK Fusion Gene and Features Associated with EGFR Mutations in Chinese Patients with Non-Small-cell Lung Cancer

[Detection of Epidermal Growth Factor Receptor Mutations in Non-Small-cell Lung Carcinoma by Direct Sequencing and Correlations with Clinicopathological Characteristics and Sample Types].

Clinicopathological Features of ALK Expression in 9889 Cases of Non-small-Cell Lung Cancer and Genomic Rearrangements Identified by Capture-Based Next-Generation Sequencing: A Chinese Retrospective Analysis.

High Feasibility of Liquid-Based Cytological Samples for Detection of EGFR Mutations in Chinese Patients with NSCLC.

Research on reliability of small specimens in detecting EGFR gene mutation in non-small cell lung cancer

Significance and Evaluation of Anaplastic Lymphoma Kinase by Immunohistochemistry in Non-Small Cell Lung Cancer.

Comparison of EML4-ALK Fusion Gene Positive Rate in Different Detection Methods and Samples of Non-Small Cell Lung Cancer.